SELLAS Life Sciences Group Inc SLS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS
-
These 16 stocks are a short seller's dream - likely losers no matter what the market does
Trading Information
- Previous Close Price
- $12.31
- Day Range
- $11.20–12.25
- 52-Week Range
- $1.39–15.88
- Bid/Ask
- $11.36 / $11.41
- Shares Outstanding
- 201.95M
- Market Cap
- $2.29B
- Volume/Avg
- 6M / 7M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 13
Valuation
|
Metric
|
SLS
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 16.63 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
SLS
Financial Strength
|
Metric
|
SLS
|
|---|---|
Quick Ratio | 18.28 |
Current Ratio | 18.83 |
Interest Coverage | — |
Quick Ratio
SLS
Profitability
|
Metric
|
SLS
|
|---|---|
Return on Assets (Normalized) | −35.21% |
Return on Equity (Normalized) | −38.30% |
Return on Invested Capital (Normalized) | −41.43% |
Return on Assets
SLS
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|&D&m%v | LOCK|BZdc& | $128B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|%BXVBy | LOCK|#<Ys> | $76B | |||
| Moderna Inc
MRNA
| LOCK|NLV&c%r | LOCK|tf | $75B | |||
| argenx SE ADR
ARGX
| LOCK|DwRZN! | LOCK|d# | $60B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|$$<f<^ | LOCK|nh | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|G##>#YC | LOCK|#!!&< | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|zC>JM?R$ | LOCK|vj>q! | $26B | |||
| BioNTech SE ADR
BNTX
| LOCK|j&KPSv | LOCK|@Nh | $24B | |||
| Incyte Corp
INCY
| LOCK|d@#>#Zl | LOCK|lK | $24B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|HPFKbcy | LOCK|FC^ | $15B |
United States